ResMed (RMD) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $253.06 +2.79%
Revenue Growth %: +6.9%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Revenue Growth %: +6.9%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $1.60, $0.07 worse than the analyst estimate of $1.67. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.14 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- TriCo Bancshares (TCBK) Tops Q3 EPS by 9c
- 1st Source Corp (SRCE) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
